Index of drugs

Recurrent infections of the upper respiratory tract. The vaccine is used prophylactically and therapeutically in children and adults.

1 ml of the vaccine contains inactivated bacteria in the amount of 50 million cellsStaphylococcus aureus50 millionStaphylococcus epidermidis, 10 millionStreptococcus salivarius, 10 millionStreptococcus pneumoniae, 10 millionStreptococcus pyogenes, 20 millionEscherichia coli, 10 millionKlebsiella pneumoniae, 10 millionHaemophilus influenzae, 20 millionCorynebacterium pseudodiphtheriticum, 10 millionMoraxella catarrhalis.

Non-specific bacterial vaccine. The active substances are suspensions of bacteria killed by high temperatures, which most often cause upper respiratory tract infections. Vaccine with immunostimulatory effect, strengthening the overall, nonspecific immunity of the immune system. At the same time, it induces a specific resistance to bacteria whose antigens are contained in the preparation. The vaccine thus protects the body against recurrent catarrh of the upper respiratory tract.

Hypersensitivity to active substances or to any of the excipients. Infectious diseases. Failure of circulation. Diseases of the kidneys and liver. Haematopoietic diseases. Systemic diseases. The use of immunosuppressive drugs.

Treatment should be preceded by a thorough medical history (with particular reference to previous vaccinations and side effects that could have been caused) and a medical examination. Treatment should not be started during the acute period of the disease. In patients undergoing immunosuppressive therapy, the response to the vaccine may be reduced - in this case, it is recommended to postpone the vaccination until the end of therapy. The vaccine may be administered during the course of the infection if the treatment has started before the infection develops.

There are no data on the use of the preparation during pregnancy and breastfeeding.

Irritation of the nasal mucosa at the injection site may occur (burning sensation, itching).

Intranasally. The treatment should be conducted twice a year in periods preceding the most unfavorable climatic conditions: in January-February and August-September, for a period of at least 2 years. The vaccine should be given every day for 6 weeks. If upper respiratory tract infections occur during vaccination, continue the treatment without increasing the dose. If you stop treatment, consult your doctor.Children from 6 months to 3 years: in 1 week, give 1 drop to the left side of the nose in the evening; in the second and third weeks, give one drop to the right and left of the nose in the evening; at 4, 5 and 6 weeks, give one drop to the right and left side of the nose in the morning and one drop to the right and left of the nose in the evening.Children from 3 to 7 years old: in the first week, give one drop to the right and left of the nose in the evening; in the second and third weeks, give one drop to the right and left side of the nose in the morning and one drop to the right and left of the nose in the evening; at 4, 5 and 6 weeks, give one drop to the right and the left side of the nose in the morning and two drops to the right and left of the nose in the evening.Adults and children over 7 years: in the first and second weeks, give one drop to the right and left of the nose in the morning and one drop to the right and left of the nose in the evening; in the third and fourth week, give one drop to the right and the left side of the nose in the morning and two drops to the right and left of the nose in the evening; in 5 and 6 weeks, give two drops to the right and left side of the nose in the morning and two drops to the right and left of the nose in the evening. The dosage method depends on the patient's response. In patients who have been hypersensitive to the bacterial antigens contained in the vaccine, the lower doses should be extended.